The genomics industry has a PR problem and it’s largely a self-made one. When I read articles about the latest in physics research and The Large Hadron Collider at CERN, I read about how the collider will be used to find new particles that will fundamentally alter our understanding of the universe. The fact that ...
The April 20, 2011 issue of the Journal of the American Medical Association, includes an editorial that speaks of the "remarkable" power of genomics for diagnosis of cancer. Citing two patient examples, it argues that fundamental advances in cost and speed of whole-genome sequencing will likely make personalized genomic medicine for cancer treatment commonplace in ...
Illumina's HiSeq 2000 running at capacity can sequence two whole human genomes per week at 30x coverage - enough for a full-blown whole genome analysis. One instrument produces 104 human genomes per year. Beijing Genomics Institute alone has purchased 128 of these instruments. The Broad has 51. And based on Illumina's 2010 Q1 10-Q filing, they've ...
The provocative title The Debt Crisis and the Human Genome belies Mike Mandels underlying message. I do worry that articles like this and the recent NY Times article A Decade Later, Human Genome Project Yields Few New Cures feed the cynics. Our society is so enamored with immediate gratification. Rome wasn't built in ...
Following an earlier post, the ruling by the federal judge 0n the BRCA patents held by Myriad has created a firestorm of controversy in the blogs and in the popular media. Check this out!: NPR: Gene Ruling Could Have Wide Implications 60 Minutes: Gene Patents The industry blog Genetic Future has sponsored an ...
The most thoughtful folks in the health care industry acknowledge that the future will be defined by molecular (aka personalized) medicine. Without being infinitely tedious, it will be a matter of measuring your body's instructions (DNA) and your present state (RNA/proteins) and prescribing a course of treatment with the most likely positive outcome and ...
GenomeQuest could have targeted consumers, the largest available market for its technology. When we entered the market in 2004, the consumer wave was a distant vision, not even on the horizon. How did we survive? We targeted the smallest segment we could find: Information Scientists and Biotech Patent Lawyers. Why? My father was a old-school ...
Brad Perriello at MassDevice interviewed me and posted the article in their popular e-newsletter on the medical device industry. You can read the interview here. Brad caught me a little off guard when he asked me what I considered to be the ethical implications of individuals having access to their genomes. In a couple ...